In addition, FLNA may protect SST2 from degradation by facilitating targeting of the receptor to a recycling pathway during long-term agonist treatment of pancreatic tumor and GH-secreting tumor cells (Peverelli et al., 2014; Vitali et al., 2016). This evidence concerns the gene SSTR2 and pancreatic neoplasm.